| Literature DB >> 25010986 |
V Wagh1, M X Doss1, D Sabour1, R Niemann1, K Meganathan1, S Jagtap1, J A Gaspar1, M A Ardestani2, S Papadopoulos2, M Gajewski3, J Winkler1, J Hescheler1, A Sachinidis1.
Abstract
FAM40B (STRIP2) is a member of the striatin-interacting phosphatase and kinase (STRIPAK) complex that is involved in the regulation of various processes such as cell proliferation and differentiation. Its role for differentiation processes in embryonic stem cells (ESCs) is till now completely unknown. Short hairpin RNA (shRNA)-mediated silencing of Fam40b expression in ESCs and differentiating embryoid bodies (EBs) led to perturbed differentiation to embryonic germ layers and their derivatives including a complete abrogation of cardiomyogenesis. Pluripotency factors such as Nanog, Oct4 and Sox2 as well as epigenetic factors such as histone acetyltransferase type B (HAT1) and DNA (cytosine-5)-methyltransferase 3-β (Dnmt3b) were highly upregulated in Fam40b knockdown EBs as compared with control and scrambled EBs. To examine the relevance of Fam40b for development in vivo, Fam40b was knocked down in developing zebrafish. Morpholino-mediated knockdown of Fam40b led to severe abnormalities of the cardiovascular system, including an impaired expression of ventricular myosin heavy chain (vmhc) and of cardiac myosin light chain 2 (cmlc2) in the heart. We identified the gene product of Fam40b in ESCs as a perinuclear and nucleolar protein with a molecular weight of 96 kDa. We conclude that the expression of Fam40b is essential for the lineage commitment of murine embryonic stem cells (mESCs) into differentiated somatic cells via mechanisms involving pluripotency and epigenetic networks.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25010986 PMCID: PMC4123067 DOI: 10.1038/cddis.2014.273
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1Generation and characterization of ESCs in which Fam40b was constitutively knocked down (KD) by transfection with pGFP-V-RS, expressing shRNA directed against the Fam40b RNA, the GFP and the puromycin resistance cassette. (a) Fluorescence microscopy of control 12-day EBs derived from ESCs transfected with the pGFP-V-RS vector without shRNA (control) and EBs derived from ESCs transfected with the pGFP-V-RS shRNA expressing vector containing 29-mers shRNA (Fam40b KD EBs) (scale bar: 50 μm). (b) Semiquantitative RT-PCR analysis of the expression of GFP and Fam40b in undifferentiated control and KD Fam40bESCs as well as in 4-, 8- and 12-day control and KD EBs generated by the hanging drop protocol. (c) Expression of the FAM40B protein during differentiation of WT ESCs (upper panel) and during differentiation of Fam40B KD ESCs. Detection has been performed with FAM40b primary antibody (sc-162799, Santa Cruz Biotechnology; 1 : 500 dilution) and with the secondary donkey anti-Goat IgG antibody (1 : 10 000 dilution). GAPDH has been detected using the anti-GAPDH antibody (1 : 25 000 dilution). (d) Densitometric analysis of the FAM40B and the corresponding GAPDH bands densities has been performed by using the ImageJ 1.47v software (National Institutes of Health, Bethesda, MD, USA) and the ratio of the FAM40B/GAPDH band densities has been blotted for the different time points of differentiation
Figure 2Transcriptome analysis of wild-type ESCs, control 12-day EBs and Fam40B KD 12-day EBs. (a) Principal component analysis of genome-wide gene expression. Each sphere represents an individual sample from a color-coded triplicate sample. (b) Visualization of k-means clustering of 5574 differentially expressed probe sets with Euclidean distance measurement and k=5 group clusters. Replicates are displayed in the vertical axis and genes in the horizontal axis. Log2 transformed signal intensities are depicted in color code. The heatmap indicates high expression levels in red, intermediate expression level in dark gray and low expression levels in green
Developmental GO BPs as well as KEGG pathways differentially regulated in KD 12-day EBs in comparison with control 12-day EBs and WT ESCs
| GO:0007507∼heart development | 20 | 9.47E−05 |
| GO:0045597∼positive regulation of cell differentiation | 16 | 4.77E−04 |
| GO:0030705∼cytoskeleton-dependent intracellular transport | 7 | 5.37E−04 |
| GO:0001568∼blood vessel development | 19 | 8.25E−04 |
| GO:0001944∼vasculature development | 19 | 0.001092 |
| GO:0001649∼osteoblast differentiation | 7 | 0.003581 |
| GO:0007417∼central nervous system development | 23 | 0.00363 |
| GO:0060348∼bone development | 11 | 0.004406 |
| GO:0007420∼brain development | 19 | 0.005137 |
| GO:0043009∼chordate embryonic development | 24 | 0.008354 |
| GO:0030324∼lung development | 10 | 0.008945 |
| mmu04310:Wnt signaling pathway | 17 | 1.00E−05 |
| mmu04810:Regulation of actin cytoskeleton | 19 | 9.47E−05 |
| mmu04340:Hedgehog signaling pathway | 8 | 0.001149 |
| mmu05414:Dilated cardiomyopathy | 10 | 0.001831 |
| mmu04360:Axon guidance | 12 | 0.002053 |
| GO:0034660∼ncRNA metabolic process | 42 | 1.16E−13 |
| GO:0034470∼ncRNA processing | 34 | 1.34E−11 |
| GO:0006396∼RNA processing | 53 | 6.21E−08 |
| GO:0019827∼stem cell maintenance | 10 | 9.91E−07 |
| GO:0040029∼regulation of gene expression, epigenetic | 14 | 8.25E−05 |
| GO:0006396∼RNA processing | 27 | 8.80E−06 |
| GO:0016070∼RNA metabolic process | 33 | 5.44E−05 |
| GO:0000154∼rRNA modification | 4 | 6.17E−04 |
| GO:0034470∼ncRNA processing | 12 | 0.001053 |
| GO:0043414∼biopolymer methylation | 8 | 0.001189 |
| GO:0009451∼RNA modification | 6 | 0.002623 |
| GO:0034660∼ncRNA metabolic process | 12 | 0.007034 |
| GO:0007507∼heart development | 54 | 1.98E−17 |
| GO:0001568∼blood vessel development | 56 | 6.00E−17 |
| GO:0048732∼gland development | 38 | 2.42E−09 |
| GO:0060348∼bone development | 28 | 4.45E−09 |
| GO:0022008∼neurogenesis | 71 | 6.88E−09 |
| GO:0030323∼respiratory tube development | 27 | 7.60E−09 |
| GO:0001822∼kidney development | 26 | 1.06E−08 |
| GO:0051216∼cartilage development | 20 | 3.07E−07 |
| GO:0016055∼Wnt receptor signaling pathway | 25 | 2.15E−06 |
| GO:0048565∼gut development | 13 | 3.38E−06 |
| GO:0035108∼limb morphogenesis | 22 | 1.10E−05 |
| GO:0048666∼neuron development | 39 | 2.18E−05 |
| GO:0008016∼regulation of heart contraction | 13 | 5.47E−05 |
| GO:0007417∼central nervous system development | 44 | 9.31E−05 |
| GO:0007219∼Notch signaling pathway | 13 | 1.22E−04 |
| GO:0030111∼regulation of Wnt receptor signaling pathway | 11 | 1.26E−04 |
| GO:0045664∼regulation of neuron differentiation | 18 | 2.37E−04 |
| GO:0031016∼pancreas development | 9 | 0.001984 |
| GO:0048286∼lung alveolus development | 7 | 0.0020672 |
| GO:0030900∼forebrain development | 22 | 0.0022447 |
| GO:0007498∼mesoderm development | 11 | 0.0038993 |
| GO:0001889∼liver development | 9 | 0.00531 |
| GO:0048567∼ectodermal gut morphogenesis | 5 | 0.0099191 |
| mmu05414:Dilated cardiomyopathy | 22 | 2.44E−07 |
| mmu04350:TGF- | 17 | 1.15E−04 |
| mmu04310:Wnt signaling pathway | 21 | 0.0013417 |
| GO:0007507∼heart development | 24 | 0.001835 |
| GO:0002076∼osteoblast development | 5 | 0.001952 |
| GO:0043414∼biopolymer methylation | 11 | 0.004197 |
| GO:0006396∼RNA processing | 37 | 0.006022 |
| mmu04910:Insulin signaling pathway | 18 | 3.68E−04 |
| mmu04810:Regulation of actin cytoskeleton | 23 | 8.58E−04 |
| mmu04310:Wnt signaling pathway | 18 | 8.99E−04 |
GOs include genes that are at least twofold up- or downregulated
Figure 3Expression levels of the genes belonging to the ‘GO:0040029∼regulation of gene expression, epigenetic' (a and b) and the expression of GO:0019827∼stem cell maintenance (c) pluripotent marker genes that are highly upregulated in the Fam40b KD 12-day EBs compared with the control 12-day EBs. (d) Gene expression of representative genes from (a–c) determined by qPCR analysis. The gene expression data of triplicates for each experimental condition are expressed as mean±S.D. (*P<0.05 for KD Fam40b 12-day versus control 12-day EBs)
Figure 4Global transcriptome analysis of WT ESCs, Scr ESCs, KD ESCs, WT 12-day, Scr 12-day and KD 12-day EBs. (a) Principal component analysis of genome-wide gene expression. Each sphere represents individual sample from a color-coded triplicate sample. (b) Visualization of k-means clustering of 5574 differentially expressed probe sets with Euclidean distance measurement and k=5 group clusters. Replicates are displayed in the vertical axis and genes in the horizontal axis. Log2 transformed signal intensities are depicted in color code. The heatmap indicates high expression levels in red, intermediate expression level in dark gray and low expression levels in green
Selected significantly regulated GO-BPs as well as KEGG pathways in KD 12-day EBs versus Scr 12-day EBs
| GO:0034660∼ncRNA metabolic process | 74 | 1.95E−20 |
| GO:0034470∼ncRNA processing | 62 | 6.29E−19 |
| GO:0006396∼RNA processing | 109 | 2.77E−15 |
| GO:0043414∼biopolymer methylation | 25 | 5.71E−07 |
| GO:0040029∼regulation of gene expression, epigenetic | 22 | 2.35E−05 |
| GO:0019827∼stem cell maintenance | 11 | 6.81E−05 |
| GO:0016125∼sterol metabolic process | 17 | 8.87E−08 |
| GO:0006749∼glutathione metabolic process | 7 | 3.66E−04 |
| GO:0001568∼blood vessel development | 23 | 5.78E−04 |
| GO:0006631∼fatty acid metabolic process | 19 | 7.00E−04 |
| mmu00100:Steroid biosynthesis | 6 | 6.18E−04 |
| mmu00052:Galactose metabolism | 7 | 8.99E−04 |
| mmu03320:PPAR signaling pathway | 11 | 0.002151043 |
| mmu00051:Fructose and mannose metabolism | 7 | 0.004894936 |
| GO:0007507∼heart development | 79 | 1.70E−18 |
| GO:0001568∼blood vessel development | 74 | 3.02E−13 |
| GO:0060537∼muscle tissue development | 48 | 2.20E−11 |
| GO:0048732∼gland development | 59 | 1.71E−10 |
| GO:0001822∼kidney development | 40 | 1.82E−10 |
| GO:0060348∼bone development | 42 | 3.45E−10 |
| GO:0051216∼cartilage development | 32 | 1.14E−09 |
| GO:0048706∼embryonic skeletal system development | 33 | 1.52E−09 |
| GO:0007420∼brain development | 71 | 2.16E−08 |
| GO:0007417∼central nervous system development | 83 | 9.98E−08 |
| GO:0022008∼neurogenesis | 107 | 8.16E−07 |
| GO:0030324∼lung development | 34 | 1.14E−06 |
| GO:0016055∼Wnt receptor signaling pathway | 37 | 2.45E−06 |
| GO:0017015∼regulation of transforming growth factor-β receptor signaling pathway | 14 | 2.69E−05 |
| GO:0001568∼blood vessel development | 30 | 2.17E−05 |
| GO:0001944∼vasculature development | 30 | 3.42E−05 |
| GO:0009966∼regulation of signal transduction | 57 | 1.41E−04 |
| GO:0019220∼regulation of phosphate metabolic process | 32 | 1.76E−04 |
| GO:0045597∼positive regulation of cell differentiation | 22 | 2.54E−04 |
| GO:0030324∼lung development | 14 | 0.00450939 |
| GO:0001822∼kidney development | 13 | 0.0087518 |
| GO:0048666∼neuron development | 25 | 0.01569382 |
| GO:0022008∼neurogenesis | 40 | 0.0181755 |
| GO:0007507∼heart development | 18 | 2.02E−04 |
| GO:0022008∼neurogenesis | 30 | 6.40E−04 |
| mmu04010:MAPK signaling pathway | 18 | 8.45E−04 |
GOs include genes that are at least twofold up- or downregulated
Figure 5Expression levels of the genes belonging to the GO:0019827∼stem cell maintenance (a) pluripotency marker genes and ‘GO:0040029∼regulation of gene expression, epigenetic' (b) that are highly upregulated in the Fam40b KD 12-day compared with the Scr 12-day EBs. The gene expression data of triplicates for each experimental condition are expressed as mean±S.D. (*P<0.05 for KD Fam40b 12-day versus Scr 12-day EBs)
Figure 6Molecular weight and cellular localization of FAM40B protein. (a) Protein lysates were prepared from undifferentiated ESCs. After separation of 40 μg protein by SDS polyacrylamide (10%) gel electrophoresis (SDS-PAGE), western blotting of the proteins was done on nitrocellulose membrane. Chemiluminescence detection of FAM40B has been performed using the Fam40b-433–450 polyclonal antibodies and anti-Mouse IgG alkaline phosphatase-conjugated secondary antibodies. (b and d) Localization of FAM40B in ESCs. ESCs were transfected with the HaloTag Flexi Vector containing the Fam40b cDNA using TurboFect. After 48 h, Fam40b was detected using the HaloTag Oregon Green ligand in the nucleoli by confocal microscopy. Normal arrows show Fam40b in the nucleoli and dashed arrows the perinuclear Fam40b. (c) The transparent light microscopy of (b). (e) After fixing of the ESCs (in d), Fam40b has also been detected by immunohistochemistry using primary Anti HaloTag pAb (1 : 500 dilution) and anti-mouse IgG Alexa Fluor 594 secondary antibodies. (f) Immunostaining of Fam40b in WT ESCs using primary anti-Fam40b antibodies (sc-162799; 1 : 200) and donkey anti goat IgG-FITC secondary antibody (sc-2024, 1 : 200) as secondary antibody (upper scan, green pseudocolor). Cells were co-stained with the nuclear marker Hoechst 33342 (scan in the middle, blue). The overlay of nuclear and Fam40b staining (f, bottom) reveals that the presence of Fam40b is not restricted to the nucleus but also extends to perinuclear or even cytoplasmic domains of the ESCs (scale bar: 10 μm)
Figure 7The in situ hybridization of Fam40b in the zebrafish heart as well as the expression of vmhc and of cardiac cmlc2 in control and Fam40b knockdown animals. (a) Digoxigenin-labeled RNA probes were prepared using RNA labeling kit and stained using BM purple. (b) The position of the atrium (arrowhead) and the ventricle (arrow) that was not beating after knockdown of Fam40b is shown. (c) Expression of vmhc in Fam40b knockdown animals was significantly impaired as compared with control animals (d) (arrows show the ventricles). Expression of cmlc2 in Fam40b knockdown animals was almost absent in ventricles and impaired in the atria (e) as compared with control (f) (upper arrows indicate ventricles and lower arrows indicate atria; one representative experiment out of five independent). Whole mount embryos were imaged on a Leica stereomicroscope fitted with a Zeiss Axiocam color camera